Lv41
500 积分 2025-02-17 加入
Trends in the drug target landscape for autoimmune diseases
4小时前
已完结
Tumour-derived small extracellular vesicles act as a barrier to therapeutic nanoparticle delivery
4小时前
待确认
Phase 3, 56-week, randomised, double-blind, placebo-controlled study utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis: OA-11 Study
1个月前
已完结
皖公网安备34019202002308
